WuXi Biologics has leased 33,000 square feet at the Discovery Labs in King of Prussia and expects to add 100 jobs by the end of this year.
The company took the King of Prussia space earlier this year and “plans to build a development lab to serve our local and global biotech and biopharma partners,” said Ruyi Shi, a WuXi Biologics spokeswoman, in an email. The company declined to elaborate, saying that no additional information was available at this time.
On Glassdoor, LinkedIn and ZipRecruiter, WuXi Biologics has job postings for research associates, scientists, quality assurance specialists and other positions involving working in a lab in King of Prussia.
Discovery Labs is a 1.6-million-square-foot campus that includes 1 million square feet of former GlaxoSmithKline manufacturing and office space at 411 Swedeland Road in Upper Merion. Earlier this year, developer Brian O’Neill announced he had teamed up with Deerfield Management Co. to launch the Center for Breakthrough Medicines in 680,000 square feet at Discovery Labs that would serve as a manufacturing facility for companies needing a place to outsource cell-and-gene therapy and other production.
A representative from Discovery Labs declined to comment on WuXi Biologics taking space in the facility.
WuXi Biologics started out in 2010 as a division of WuXi AppTec Co. Ltd., a Shanghai-based company that provides research and development and manufacturing services to pharmaceutical, biotech and medical device companies. WuXi AppTec has a significant presence in the region at the Philadelphia Navy Yard and is among the largest tenants at the South Philadelphia campus, occupying more than 380,000 square feet of space. The company employs more than 600 people at the Navy Yard.
The company recently completed a third $38 million, 95,000-square-foot office and laboratory building at 400 Rouse Blvd. for its advanced therapies business unit.
WuXi Biologics was spun out of WuXi AppTec in 2015 and went public in 2017 on the Hong Kong Stock Exchange. It initially started out providing cell development and other related services but then expanded into discovery, development, testing and manufacturing. It helps facilitate taking a concept through commercialization for the pharmaceutical industry. At the end of last year, the company had 250 drugs in pre-clinical development stage, early and late-phase development.
The company has also said it plans to start construction on a new 100,000-square-foot manufacturing facility in Worcester, Massachusetts, during the second quarter.